Erythema annulare centrifigum
Also known as: Erythema, Erythematous, Inflamed, Inflammation
Methodology & AI Transparency ⓘ
Erythema annulare centrifigum Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Erythema annulare centrifigum (also termed Erythema or Erythematous) (ICD-10 L53.1) is stratified through or targeted biologics [Erythema annulare centrifigum L53.1], pairing targeted symptom control with longitudinal Fasting Lipids & in Erythema annulare centrifigum (L53.1: ALT (if systemic) surveillance.
- 2 Real-world patient consensus: Synonyms for Erythema annulare centrifigum (L53.1): Erythema, Erythematous, Inflamed (Skin & Dermatology).
- 3 Typical cash cost range: Differential triage of Erythema annulare centrifigum (L53.1) utilizes or targeted biologics [Erythema annulare centrifigum L53.1].
- 4 Top reported side effects / signs: Objective lab/clinical target for Erythema annulare centrifigum: Affected Body Surface in Erythema annulare centrifigum (L53.1: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L53.1)) and Fasting Lipids & in Erythema annulare centrifigum (L53.1: ALT (if systemic).
Ask our AI Specialists anything about Erythema annulare centrifigum
What Is Erythema annulare centrifigum?
Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Erythema annulare centrifigum (also termed Erythema or Erythematous) (ICD-10 L53.1) is stratified through or targeted biologics [Erythema annulare centrifigum L53.1], pairing targeted symptom control with longitudinal Fasting Lipids & in Erythema annulare centrifigum (L53.1: ALT (if systemic) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Erythema annulare centrifigum (ICD-10 L53.1) is driven by epidermal barrier filaggrin/ceramide in Erythema annulare centrifigum (L53.1: disruption); specialists in Dermatology: Acne, Eczema, Psoriasis & Rosacea monitor Fasting Lipids & in Erythema annulare centrifigum (L53.1: ALT (if systemic) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Erythema annulare centrifigum (L53.1): persistent erythematous plaques, in Erythema annulare centrifigum (L53.1: scaly patches, pruritic)
- • Secondary Erythema annulare centrifigum clinical sign: compromised epidermal barrier in Erythema annulare centrifigum (L53.1: with dryness, fissuring,)
- • Symptom flares in Erythema annulare centrifigum correlating with Affected Body Surface in Erythema annulare centrifigum (L53.1: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L53.1)
- • Functional skin & dermatology impact requiring or targeted biologics [Erythema annulare centrifigum L53.1] evaluation (L53.1)
Erythema annulare centrifigum Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L53.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Erythema annulare centrifigum (L53.1: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L53.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Erythema annulare centrifigum (L53.1: ALT (if systemic) | Within baseline reference limits (L53.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Erythema annulare centrifigum (L53.1: & hs-CRP) | 25(OH)D 40–65 ng/mL (L53.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Erythema annulare centrifigum
Treatment selection for Erythema annulare centrifigum depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erythema annulare centrifigum)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of baricitinib in patients with systemic lupus erythematosus: an: What a 1,655-Participant Study Found The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. RMD open • 2023-08-15 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 37604638 ↗ |
| New Insights on Anifrolumab reduces flare rates in patients with moderate to severe systemic: What a 366-Participant Study Found Analyses of pooled TULIP-1 and TULIP-2 data support that anifrolumab reduces flares while permitting glucocorticoid taper in patients with SLE. Lupus • 2021-07-15 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 33977796 ↗ |
| New Insights on Benefits and safety of piclidenoson in plaque psoriasis skin flare-ups: Results: What a 529-Participant Study Found Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-06-15 • Phase III Randomized Trial | N = 529 | 93/100 | PMID 38279575 ↗ |
| New Insights on Benefits and safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus:: What a 367-Participant Study Found Consistent with the well-established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety... Arthritis & rheumatology (Hoboken, N.J.) • 2026-06-15 • Phase III Randomized Trial | N = 367 | 93/100 | PMID 41466456 ↗ |
| New Insights on Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines: What a 1,747-Participant Study Found Combinatorial analysis of four molecular biomarkers revealed subsets of SLE patients that discriminated by disease manifestations, concomitant medication use, geography, time to severe flare and SRI-4 response. Rheumatology (Oxford, England) • 2021-11-03 • Phase III Randomized Trial | N = 1,747 | 90/100 | PMID 33580248 ↗ |
Erythema annulare centrifigum Patient Community & “People Like Me” Threads
Filter Erythema annulare centrifigum community threads and patient logs by age, biological sex, dosage, and treatment duration.